MSCs migrate to tumor sites via the CXCR4/SDF-1 signaling axis and remodel the immunosuppressive microenvironment by secreting TNF-α and IL-1β, thereby enhancing PD-1 antibody delivery efficiency [14]. The gene discussed is CXCL12; the disease is neoplasm.